Daniel Lynch Biography and Net Worth

Daniel (Dan) joined SpringWorks at the company’s launch in 2017 and is Chairman of the Board of Directors. He is currently Executive Venture Partner at GV. Since 2007, Dan has advised and served as executive chairman or member of the boards for a number of biopharmaceutical companies, including Stromedix (until its acquisition by Biogen Idec in February 2012), Avila Therapeutics (acquired by Celgene Corporation), Nimbus Discovery, Edimer Pharmaceuticals, Ember Therapeutics, Proclara Biosciences, Surface Oncology, Sesen Bio (formerly Eleven Biotherapeutics), eGenesis Bio and BIND Biosciences. Dan also served as entrepreneur in residence and venture partner at Third Rock Ventures and was a senior advisor at the firm until 2021. He currently serves on the boards of bluebird bio, Blueprint Medicines, Translate Bio, Xilio Therapeutics, and Alpha Omega SPAC. Previously, Dan served as CEO and CFO of ImClone Systems Corporation. As CEO, he led the company through a significant turnaround, helping to restore its reputation and secure FDA approval of ERBITUX (cetuximab), a novel cancer treatment. As CFO, Dan led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he held several financial positions at Bristol-Myers Squibb for more than 15 years. For five years, he served on the board of directors and the audit committee of U.S. Oncology, Inc. until acquisition by McKesson in 2010. Dan received his MBA from the Darden Graduate School of Business Administration at the University of Virginia and a B.A. in mathematics from Wesleyan University.

What is Daniel Lynch's net worth?: The estimated net worth of Daniel Lynch is at least $3.92 million as of February 20th, 2025. Mr. Lynch owns 82,944 shares of SpringWorks Therapeutics stock worth more than $3,915,786 as of March 26th. This net worth approximation does not reflect any other investments that Mr. Lynch may own. Learn More about Daniel Lynch's net worth.
How do I contact Daniel Lynch?: The corporate mailing address for Mr. Lynch and other SpringWorks Therapeutics executives is 100 WASHINGTON BOULEVARD, STAMFORD CT, 06902. SpringWorks Therapeutics can also be reached via phone at 203-883-9490 and via email at investors@springworkstx.com. Learn More on Daniel Lynch's contact information.
Has Daniel Lynch been buying or selling shares of SpringWorks Therapeutics?: During the past quarter, Daniel Lynch has sold $12,420,972.00 in shares of SpringWorks Therapeutics stock. Most recently, Daniel Lynch sold 47,600 shares of the business's stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $60.22, for a transaction totalling $2,866,472.00. Following the completion of the sale, the director now directly owns 82,944 shares of the company's stock, valued at $4,994,887.68. Learn More on Daniel Lynch's trading history.
Who are SpringWorks Therapeutics' active insiders?: SpringWorks Therapeutics' insider roster includes Bhavesh Ashar (Insider), Badreddin Edris (COO), Julie Hambleton (Director), Saqib Islam (CEO), Daniel Lynch (Director), Daniel Pichl (Chief People Officer), L. Smith (Insider), and Stephen Squinto (Director). Learn More on SpringWorks Therapeutics' active insiders.
Are insiders buying or selling shares of SpringWorks Therapeutics?: In the last year, insiders at the sold shares 12 times. They sold a total of 460,766 shares worth more than $25,242,355.68. The most recent insider tranaction occured on March, 3rd when COO Badreddin Edris sold 20,000 shares worth more than $1,084,600.00. Insiders at SpringWorks Therapeutics own 7.6% of the company. Learn More about insider trades at SpringWorks Therapeutics.
Information on this page was last updated on 3/3/2025.

Daniel Lynch Insider Trading History at SpringWorks Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/20/2025	Sell	47,600	$60.22	$2,866,472.00	82,944
2/14/2025	Sell	400	$60.00	$24,000.00	130,544
2/10/2025	Sell	175,000	$54.46	$9,530,500.00	130,944

Daniel Lynch Buying and Selling Activity at SpringWorks Therapeutics

SpringWorks Therapeutics Company Overview

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Today's Range

Now: $46.51

$45.88

$47.51

50 Day Range

MA: $47.22

$33.48

$59.93

2 Week Range

Now: $46.51

$28.21

$62.00

Volume

1,006,972 shs

Average Volume

1,274,224 shs

Market Capitalization

$3.49 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76